公司簡介
In 2016, Celltrion received marketing authorization for Remsima in the U.S. which occupies half of the antibody biologics market in the world. Remsima, as the first approved biosimilar monoclonal antibodies (mAbs), has become the first mover in the US market, and is expected to have a priceless effect for attaining massive market domination. Domestically, Remsima possesses a total sales volume around 1 trillion KRW and it is expected to be the first single pharmaceutical item to reach sales in trillions of KRW with a total turnover of 20 trillion KRW of the 90 publicly traded pharmaceutical companies. Growth potential of Celltrion is perceived as the birth of new growth engine and an anchor company to lead the future of Korean economy and industry following the manufacturing industries of Korea such as heavy industry, automobile and semiconductor industry.
營業性質
- 營業性質：
- 製造商
- 產業類別：
- 醫療護理
- 主要商品服務：
醫療服務